GO:0005154 epidermal growth factor receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005154 epidermal growth factor receptor binding describes the molecular function of selectively interacting with an epidermal growth factor receptor (EGFR).
• This binding event is the first step in EGFR activation and triggers receptor dimerization, autophosphorylation, and downstream signaling.
• Key ligands include EGF, TGF-alpha, amphiregulin, betacellulin, heparin-binding EGF, and epiregulin, while EGFR itself is the major receptor.
• Dysregulated EGFR binding and signaling are central to many epithelial cancers, including lung, colorectal, and head and neck cancers.
• The function is studied using binding assays, structural biology, CRISPR knockout/knock-in models, and high-throughput screening.
• EDITGENE provides CRISPR cell models and screening services to dissect EGFR-binding mechanisms and therapeutic resistance.
Description
Epidermal growth factor receptor binding (GO:0005154) is a molecular function that enables a protein or ligand to selectively bind to an epidermal growth factor receptor (EGFR). This interaction is the initiating event in EGFR-mediated signal transduction, which controls cell proliferation, survival, migration, and differentiation. The QuickGO definition states that this function encompasses binding to an epidermal growth factor receptor, and it includes synonyms such as EGF receptor binding, TGF-alpha receptor binding, and EGFR ligand activity. Because EGFR signaling is frequently deregulated in cancer and other diseases, understanding the molecular details of receptor binding is essential for both basic research and therapeutic development. Researchers study this function to identify new ligands, characterize binding affinities, and design inhibitors or antibodies that block pathological EGFR activation.
epidermal growth factor receptor binding At A Glance
| GO ID | GO:0005154 |
|---|---|
| GO term | epidermal growth factor receptor binding |
| Ontology | molecular_function |
| Synonym | EGF receptor binding; EGF receptor ligand; TGF-alpha receptor binding; transforming growth factor alpha receptor binding |
| Major function | Binding to an epidermal growth factor receptor, initiating receptor activation and downstream signaling. |
| Major ligands | EGF, TGF-alpha, amphiregulin, betacellulin, heparin-binding EGF, epiregulin. |
| Major receptor | EGFR (ERBB1), a member of the ERBB family of receptor tyrosine kinases. |
| Related processes | EGFR dimerization, autophosphorylation, MAPK and PI3K-AKT signaling. |
| Disease relevance | Epithelial cancers, including lung, colorectal, and head and neck cancers. |
What Is GO:0005154?
In simple terms, GO:0005154 describes the ability of a molecule to physically attach to an epidermal growth factor receptor. According to the QuickGO definition, it is the binding to an epidermal growth factor receptor. This function is typically mediated by extracellular ligands such as EGF or TGF-alpha, which interact with the extracellular domain of EGFR and related receptors. The term is classified as a molecular function and is distinct from downstream signaling events, although binding is a prerequisite for receptor activation.
Why Is epidermal growth factor receptor binding Important in Cell Biology?
Epidermal growth factor receptor binding is critically important because it governs the first step of a signaling axis that is mutated or overactivated in a wide range of human cancers and other diseases. The binding event determines which ligands activate EGFR, how strongly the receptor signals, and how cells respond to their environment. Moreover, therapeutic strategies such as monoclonal antibodies and tyrosine kinase inhibitors often target either the ligand-binding interface or the downstream consequences of receptor activation. Therefore, precise characterization of EGFR-binding interactions is essential for understanding disease mechanisms and for developing effective targeted therapies.
• Initiates EGFR signaling, a master regulator of cell proliferation and survival.
• Determines ligand specificity and signaling amplitude in normal and cancer cells.
• Frequently dysregulated in epithelial cancers such as lung, colorectal, and breast cancer.
• Targeted by therapeutic antibodies and small-molecule inhibitors.
• Involved in viral entry, including human papillomavirus 16 endocytosis.
• Affected by environmental chemicals such as benzotriazole UV stabilizers.
• Provides a model system for studying receptor tyrosine kinase activation mechanisms.
• Enables high-throughput screening for new EGFR-binding ligands and inhibitors.
• Supports structural biology studies of ligand-receptor interfaces.
• Underpins CRISPR-based functional genomics of EGFR pathway genes.
Molecular Mechanism of epidermal growth factor receptor binding
Ligand recognition and binding to EGFR
In simple terms: A ligand such as EGF docks onto the outside of the EGFR receptor.
The binding function begins when a soluble ligand, such as EGF or TGF-alpha, recognizes and binds to the extracellular domain of EGFR. This interaction is mediated by specific residues in the ligand and the receptor, and it exhibits high affinity and selectivity. The binding event is the defining activity of GO:0005154 and is required for all subsequent signaling.
Receptor dimerization and activation
In simple terms: After binding, two receptor molecules pair up and switch on.
Ligand binding induces a conformational change in EGFR that promotes receptor dimerization, typically forming homodimers or heterodimers with other ERBB family members. Dimerization brings the intracellular kinase domains into close proximity, enabling trans-autophosphorylation and full activation. This step is a direct consequence of the binding function and is essential for signal propagation.
Downstream signaling cascades
In simple terms: Activated EGFR sends signals to the cell's control centers.
Once activated, EGFR phosphorylates tyrosine residues that serve as docking sites for adaptor proteins, leading to activation of the MAPK and PI3K-AKT pathways. These cascades regulate gene expression, cell cycle progression, and survival. The intensity and duration of signaling are influenced by the specific ligand that binds, linking GO:0005154 to diverse cellular outcomes.
Regulation of binding availability
In simple terms: Cells control how much receptor is available for binding.
The availability of EGFR for ligand binding is regulated by receptor expression levels, trafficking, and negative feedback mechanisms. For example, receptor internalization and degradation can limit the duration of binding and signaling. Additionally, environmental factors such as UV stabilizers can disrupt EGFR signaling, highlighting the sensitivity of this function to external cues.
Key Genes Involved in GO:0005154 epidermal growth factor receptor binding
The following genes encode the major ligands, receptors, and signaling components that participate in or regulate epidermal growth factor receptor binding (GO:0005154).
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGF | Primary ligand that binds EGFR | Model ligand for binding assays and structural studies |
| TGFA | Ligand that binds and activates EGFR | Implicated in cancer and wound healing |
| AREG | Ligand of EGFR | Autocrine growth factor in carcinomas |
| BTC | Ligand of EGFR and ERBB4 | Pancreatic and other cancers |
| HBEGF | Ligand of EGFR and ERBB4 | Implicated in cancer and inflammation |
| EREG | Ligand of EGFR and ERBB4 | Colorectal and other cancers |
| EGFR | Receptor tyrosine kinase that binds ligands | Central to cancer and targeted therapy |
| ERBB2 | Heterodimerization partner of EGFR | Amplified in breast and other cancers |
| ERBB3 | Heterodimerization partner | PI3K signaling activation |
| ERBB4 | Heterodimerization partner | Development and cancer |
| GRB2 | Adaptor protein downstream of EGFR | Links EGFR to MAPK pathway |
| SHC1 | Adaptor protein downstream of EGFR | Activates RAS-MAPK signaling |
| PIK3CA | Catalytic subunit of PI3K | Mediates EGFR-driven PI3K-AKT signaling |
| AKT1 | Serine/threonine kinase | Survival signaling downstream of EGFR |
| MAPK1 | Mitogen-activated protein kinase | Proliferation signaling downstream of EGFR |
| STAT3 | Transcription factor | EGFR-driven gene expression |
| SRC | Non-receptor tyrosine kinase | Modulates EGFR signaling |
How Is epidermal growth factor receptor binding Regulated?
Epidermal growth factor receptor binding is regulated at multiple levels. Receptor availability is controlled by gene expression, receptor trafficking, and recycling. Ligand production and shedding are regulated by proteases such as ADAM family members. Negative feedback loops, including those involving ERK-mediated phosphorylation of EGFR, dampen signaling after activation. Additionally, environmental chemicals like benzotriazole UV stabilizers can disrupt EGFR signaling, indicating that external agents can modulate this function. In cancer, mutations and amplifications in EGFR or its partners can lead to constitutive activation independent of ligand binding, altering the regulatory landscape.
epidermal growth factor receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Non-small cell lung cancer, colorectal cancer | CRISPR knockout and point-mutation models in cancer cell lines |
| TGFA | Cancer progression, wound healing | Overexpression and knockout in epithelial cells |
| ERBB2 | Breast cancer, gastric cancer | Knock-in of activating mutations |
| PIK3CA | Colorectal cancer, breast cancer | Point mutation knock-in to study downstream signaling |
| HPV16 E5 | Viral entry and endocytosis | Knockout of EGFR in HPV infection models |
EGFR binding in epithelial cancers
Dysregulated EGFR binding and signaling are hallmarks of many epithelial cancers, including non-small cell lung cancer, colorectal cancer, and head and neck squamous cell carcinoma. Overexpression of EGFR or its ligands, such as TGF-alpha, can drive tumor growth and survival. Mutations in the EGFR kinase domain can also render the receptor constitutively active, bypassing the need for ligand binding. Therapies targeting EGFR, such as cetuximab and erlotinib, aim to block these pathological interactions.
Resistance to anti-EGFR therapies
Resistance to anti-EGFR therapies frequently emerges through secondary mutations in EGFR or activation of parallel signaling pathways. For example, the EGFR T790M mutation reduces drug binding while preserving ATP affinity, and MET amplification can bypass EGFR blockade. Understanding the binding function of EGFR is crucial for designing next-generation inhibitors that overcome resistance.
EGFR binding in viral infection
EGFR binding is exploited by some viruses for entry. Human papillomavirus 16 (HPV16) endocytosis requires EGFR and Abl2 kinase activity, linking GO:0005154 to viral pathogenesis. This highlights the broader biological relevance of EGFR-binding interactions beyond cancer.
Environmental disruption of EGFR signaling
Benzotriazole UV stabilizers, common environmental contaminants, have been shown to disrupt EGFR signaling in human cells. This suggests that exogenous chemicals can interfere with EGFR binding or downstream events, with potential implications for human health.
From epidermal growth factor receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of EGFR abolish ligand-induced signaling? | EGFR knockout cell lines |
| How does a specific EGFR mutation affect ligand binding? | Point-mutation knock-in of EGFR variants |
| Can a tagged EGFR be used to track binding dynamics? | Knock-in of fluorescent or affinity tags |
| What is the effect of EGFR overexpression on proliferation? | Overexpression models in epithelial cells |
| Which genes modulate sensitivity to EGFR inhibitors? | CRISPR library screening |
| How does a ligand mutation alter receptor activation? | Point mutation of ligand genes such as EGF |
How to Study the epidermal growth factor receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | Characterizing ligand-EGFR interactions |
| X-ray crystallography | Three-dimensional structure | Visualizing binding interfaces |
| Western blot | Protein phosphorylation | Monitoring EGFR activation |
| Immunoprecipitation | Protein-protein interactions | Detecting EGFR complexes |
| CRISPR knockout screening | Gene function on a genome-wide scale | Identifying regulators of EGFR signaling |
| RNA-seq | Transcriptional changes | Downstream effects of EGFR activation |
| Flow cytometry | Cell surface receptor levels | Quantifying EGFR expression |
Binding assays
Direct binding assays, such as surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC), measure the affinity and kinetics of ligand-EGFR interactions. These methods provide quantitative parameters like KD and are essential for characterizing GO:0005154.
Structural biology
X-ray crystallography and cryo-electron microscopy have revealed the atomic details of ligand-bound EGFR dimers. These structures inform the design of inhibitors and antibodies that block binding.
Cell-based signaling assays
Phosphorylation-specific antibodies and luciferase reporters are used to monitor EGFR activation and downstream signaling in cells. These assays link binding events to functional outcomes.
CRISPR screening
Genome-wide CRISPR knockout screens can identify genes that regulate EGFR binding and signaling, revealing new therapeutic targets. Such screens are powerful for unbiased discovery.
How CRISPR Can Be Used to Study GO:0005154 epidermal growth factor receptor binding
Knockout
CRISPR knockout of EGFR or its ligands can abolish specific binding interactions and reveal their contribution to signaling and disease. Knockout cell lines are valuable for validating drug targets and understanding resistance mechanisms.
Point Mutation
Point mutations can be introduced into EGFR or ligand genes to mimic cancer-associated variants, such as EGFR T790M, and to study their impact on binding affinity and drug sensitivity. These models are crucial for precision medicine.
Knock-in
Knock-in of tagged versions of EGFR (e.g., GFP or HA) allows real-time tracking of receptor localization and binding dynamics in live cells. This approach provides spatial and temporal resolution of GO:0005154.
Overexpression
Overexpression of EGFR or its ligands can mimic the gene amplification seen in cancers and is used to study oncogenic signaling and drug responses. Such models help identify vulnerabilities in EGFR-driven tumors.
How EDITGENE Supports epidermal growth factor receptor binding Research
Researchers studying epidermal growth factor receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor activation, downstream signaling, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling functional validation of EGFR-binding mechanisms and accelerating drug discovery.
Contact EDITGENE today to design your custom CRISPR model for epidermal growth factor receptor binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| Itga5 Knockout MOC2 Cell Line | EDJ-KQ59 | Mouse | 16402 | Details Get a Quote |
| Itga5 Knockout MC-38 Cell Line | EDJ-KQ92 | Mouse | 16402 | Details Get a Quote |
| TGFA Knockout HEK293 Cell Line | EDJ-KQ241 | Human | 7039 | Details Get a Quote |
| SOCS5 Knockout HEK293 Cell Line | EDJ-KQ528 | Human | 9655 | Details Get a Quote |
| AREG Knockout HEK293 Cell Line | EDJ-KQ607 | Human | 374 | Details Get a Quote |
| ERBB4 Knockout HEK293 Cell Line | EDJ-KQ655 | Human | 2066 | Details Get a Quote |
| EREG Knockout HEK293 Cell Line | EDJ-KQ656 | Human | 2069 | Details Get a Quote |
| SHC1 Knockout HEK293 Cell Line | EDJ-KQ659 | Human | 6464 | Details Get a Quote |
| VAV3 Knockout HEK293 Cell Line | EDJ-KQ1338 | Human | 10451 | Details Get a Quote |
| VAV2 Knockout HEK293 Cell Line | EDJ-KQ1340 | Human | 7410 | Details Get a Quote |
| CCDC88A Knockout HEK293 Cell Line | EDJ-KQ2314 | Human | 55704 | Details Get a Quote |
| HBEGF Knockout HEK293 Cell Line | EDJ-KQ2392 | Human | 1839 | Details Get a Quote |
| CNOT9 Knockout HEK293 Cell Line | EDJ-KQ2609 | Human | 9125 | Details Get a Quote |
| EFEMP1 Knockout HEK293 Cell Line | EDJ-KQ3298 | Human | 2202 | Details Get a Quote |
| ATXN2 Knockout HEK293 Cell Line | EDJ-KQ3821 | Human | 6311 | Details Get a Quote |
- 1
- 2
- Next Page »
Frequently Asked Questions About epidermal growth factor receptor binding
What is epidermal growth factor receptor binding?
Epidermal growth factor receptor binding (GO:0005154) is a molecular function defined as binding to an epidermal growth factor receptor, typically by ligands such as EGF or TGF-alpha.
What genes are involved in epidermal growth factor receptor binding?
Key genes include EGFR, EGF, TGFA, AREG, BTC, HBEGF, and EREG, which encode the receptor and its ligands.
How does EGFR binding lead to cell signaling?
Ligand binding induces EGFR dimerization and autophosphorylation, which activates downstream MAPK and PI3K-AKT pathways.
Why is EGFR binding important in cancer?
Dysregulated EGFR binding and signaling drive proliferation and survival in many epithelial cancers, making it a major therapeutic target.
What are the synonyms for GO:0005154?
Synonyms include EGF receptor binding, EGF receptor ligand, TGF-alpha receptor binding, and transforming growth factor alpha receptor binding.
What methods are used to study EGFR binding?
Common methods include surface plasmon resonance, X-ray crystallography, co-immunoprecipitation, and CRISPR screening.
Can CRISPR be used to study EGFR binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect EGFR binding mechanisms.
What diseases are associated with EGFR binding?
Diseases include non-small cell lung cancer, colorectal cancer, head and neck cancer, and viral infections such as HPV16.
How does resistance to anti-EGFR therapy occur?
Resistance can arise from secondary EGFR mutations (e.g., T790M) or activation of bypass pathways like MET amplification.
What services does EDITGENE offer for EGFR research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, library screening, and bioinformatics services.
Conclusion
Epidermal growth factor receptor binding (GO:0005154) is a fundamental molecular function that initiates one of the most important signaling pathways in cell biology. Its dysregulation is central to many cancers and other diseases, making it a prime target for therapeutic intervention. Advances in structural biology, CRISPR genome editing, and high-throughput screening continue to deepen our understanding of this interaction and its role in health and disease.
References
- 1. Sabbah DA et al.. 2020. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.. Curr Top Med Chem 20(10):815-834 PMID: 32124699
- 3. Ferguson KM et al.. 2020. Insulin and epidermal growth factor receptor family members share parallel activation mechanisms.. Protein Sci 29(6):1331-1344 PMID: 32297376
- 4. Sondermann NC et al.. 2024. Benzotriazole UV stabilizers disrupt epidermal growth factor receptor signaling in human cells.. Environ Int 190:108886 PMID: 39024829
- 5. Sung JS et al.. 2024. Epidermal Growth Factor Receptor (EGFR) Inhibitors Screened from Autodisplayed Fv-Antibody Library.. Bioconjug Chem 35(9):1324-1334 PMID: 39197031
- 6. London M et al.. 2020. Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies.. Cell Biol Int 44(6):1267-1282 PMID: 32162758
- 7. Zhou J et al.. 2021. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.. J Exp Clin Cancer Res 40(1):328 PMID: 34663410
- 8. Bannach C et al.. 2020. Epidermal Growth Factor Receptor and Abl2 Kinase Regulate Distinct Steps of Human Papillomavirus 16 Endocytosis.. J Virol 94(11) PMID: 32188731
